{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(7)"],"submitter":["Auclin E"],"funding":["the Contrato Juan Rodes 2020","Ayuda de la Acción Estratégica en Salud-ISCIII FIS 2021","Ayuda SEOM-Juan Rodés 2020"],"journal":["Translational Lung Cancer Research"],"pagination":["2427-2436"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12337063"],"repository":["biostudies-literature"],"pubmed_title":["Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort—the smile study"],"pmcid":["PMC12337063"],"funding_grant_id":["JR20/00019","PI21/01653"],"pubmed_authors":["Di Federico A","Minatta J","Aboubakar F","De Giglio A","Tagliamento M","Sacco G","Gerber H","Girard N","Albarran-Artahona V","Epaillard N","Du Rusquec P","Moran-Bueno T","Berthou H","Recondo G","Gorria T","Jimenez-Munarriz B","Mezquita L","Blaquier J","Lopez-Castro R","Besse B","Laguna J","Auclin E"],"additional_accession":[]},"is_claimable":false,"name":"Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort—the smile study","description":null,"dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-05-29T17:23:17.417Z","creation":"2026-04-08T05:36:50.367Z"},"accession":"S-EPMC12337063","cross_references":{}}